Cover Image
市場調查報告書

市場進入的課題:非小細胞肺癌 (歐盟5國)

Market Access Impact (EU5) - NSCLC

出版商 FirstWord 商品編碼 382822
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
市場進入的課題:非小細胞肺癌 (歐盟5國) Market Access Impact (EU5) - NSCLC
出版日期: 2017年08月01日 內容資訊: 英文
簡介

本報告依據以法國,義大利,德國,西班牙,英國的腫瘤專門醫生150名為對象的非小細胞肺癌治療藥的處方趨勢調查的結果,提供主要9個品牌藥的市場佔有率的影響因素,各個產品的市場進入的妨礙要素、障礙等彙整資料。

調查課題

  • 市場進入的各種障礙
    • 醫生最大量開立處方的品牌為?
    • 受到各種障礙影響的處方箋數為?
    • 哪個障礙影響最大?
  • 各品牌的障礙的影響
    • 各品牌開立處方的醫生數為?沒開立處方但考慮的數為?
    • 不開立處方的理由為?替代處方為何?
    • 各品牌的市場佔有率為何?

調查對象

  • Avastin (bevacizumab; Roche)
  • Cyramza (ramucirumab; Eli Lilly)
  • Giotrif (afatinib; Boehringer Ingelheim)
  • Iressa (gefitinib; AstraZeneca)
  • Opdivo (nivolumab; BMS)
  • Portrazza (necitumumab; Eli Lily)
  • Tarceva (erlotinib; Roche)
  • Xalkori (crizotinib; Pfizer/Merck Group)
  • Zykadia (ceritinib; Novartis)

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Eliminating prescription barriers could break the tie at the top of the market

The two leading brands in the EU5 non-small cell lung cancer (NSCLC) market are tied for market share, but one of them benefits more from market barriers that prevent oncologists from prescribing competing treatments. Eliminating those barriers could help the other leading brand take a narrow, but significant lead.

Get the details in Market Access Impact: NSCLC (EU5).

You'll see how widely prescribed your brand is, and learn how 7 barriers affect your market share. You'll also find out how much share you win and lose, who you take share from, and who gets your lost share.

Based on a survey of 150 medical oncologists from the EU5 countries (France, Germany, Italy Spain, UK), the report covers 10 major therapies from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Merck Sharpe & Dohme, Novartis, Pfizer/Merck Group, and Roche.

Not your market? Click here to see the US report

Request sample pages

Top Takeaways

  • Market access is a key concern: While barriers affect over 15% of prescriptions overall, market access barriers are responsible for nearly a third of that impact.
  • More brands lose out: Barriers cause more brands to lose market share than to gain, and the losses tend to be bigger than gains.
  • Tie-breaker: The two leading brands have equal market share, but eliminating barriers would cause one of them to lose enough share to give the other a narrow lead.
  • Problem areas: Some barriers have an outsized effect on some brands, e.g., reimbursement and formulary availability are the issues for the brand in the last-place.
  • Barrier effect is widespread: 45-65% of doctors experience at least one or more barriers with every surveyed brand.
  • Overall perception is good: Most doctors either prescribe, or would consider prescribing all of the surveyed brands, and no more than 5% of doctors are unaware of any given brand.

Insight into 10 Major NSCLC Drugs

  • Avastin (bevacizumab; Roche)
  • Cyramza (ramucirumab; Eli Lilly)
  • Giotrif (afatinib; Boehringer Ingelheim)
  • Iressa (gefitinib; AstraZeneca)
  • Keytruda (pembrolizumab; Merck Sharpe & Dohme)
  • Opdivo (nivolumab; Bristol-Myers Squibb)
  • Tagrisso (osimertinib; AstraZeneca)
  • Tarceva (erlotinib; Roche)
  • Xalkori (crizotinib; Pfizer/Merck Group)
  • Zykadia (ceritinib; Novartis)

Exploring Market Access Barriers

Market Access Impact: NSCLC (EU5) explores key issues affecting drug manufacturers. You'll learn:

How barriers affect market access:

  • What brands do doctors prescribe the most?
  • How many prescriptions do barriers affect?
  • Which barriers have the biggest impact?

How barriers affect your brand:

  • How many doctors prescribe your brand? How many don't, but would consider it?
  • Why don't doctors prescribe your brand? What do they prescribe instead?
  • Which competing brands does your brand take market share from?

A Report Based on Expert Knowledge

We surveyed 150 medical oncologists-30 from each EU5 country (France, Italy, Germany, Spain, UK)-chosen from the largest community of validated physicians in the world.

All respondents:

  • Have been practicing for 2+ years
  • Prescribed at least one of the listed products
  • Seen at least 5 patients with NSCLC in total in the last month

We conducted the survey between August 1st and 16th, 2017.

Money Back Guarantee!

At FirstWord, we stand behind our reports. If you're not completely satisfied, we'll refund your money. Guaranteed.

About FirstWord

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.

FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company's success.

FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.

Learn more at www.firstwordgroup.com.

Table of Contents

1. What are market barriers?

2. About this report

3. About the survey

4. Brands included in the survey

5. Executive summary

Back to Top